Journal of Thrombosis and Haemostasis : Jth
-
Publication Venue For
-
Comparison of locally measured activated partial thromboplastin time (aPTT) to central laboratory aPTT when measuring reversal of dabigatran using idarucizumab.
14:30-30.
2016
-
VTE Prevention in Acutely Ill Medical Patients with Extended Duration Betrixaban - A Multicenter, Randomized, Active-Controlled Efficacy and Safety Study Comparing Extended Duration Betrixaban with Standard of Care Enoxaparin.
14:8-9.
2016
-
Initial results of the re-verse AD trial: idarucizumab reverses the anticoagulant effects of dabigatran in patients in an emergency setting of major bleeding, urgent surgery, or interventions.
13:85-85.
2015
-
Management of reproductive hemorrhagic complications.
13:58-59.
2015
-
Whole-exome sequencing identifies novel risk variants for thrombotic storm.
11:7-7.
2013
-
An ex vivo evaluation of the hemostatic effects of plasma-derived C1 inhibitor.
11:854-854.
2013
-
Association of perioperative inflammation and coagulation status with delayed VTE after major surgery.
11:1009-1009.
2013
-
Evaluation of thrombin generation in sickle cell patients and correlation to clinical disease.
9:836-836.
2011
-
Induction of tissue factor expression in monocytes by the platelet factor 4/heparin/antibody complex is mediated by MEK1 and pERK1/2.
9:265-266.
2011
-
Hypercoagulation and thrombophilia in liver disease..
6:2-9.
2008
-
Post-coronary intervention recurrent ischemia in the presence of adequate platelet inhibition by dual antiplatelet therapy: what are we overlooking?.
5:2300-2301.
2007
-
Restoring hemostatic thrombin generation at the time of cutaneous wounding does not normalize healing in hemophilia B..
5:1577-1583.
2007
-
Tissue factor around dermal vessels has bound factor VII in the absence of injury..
5:1403-1408.
2007
-
Bleeding events and other complications during pregnancy and childbirth in women with von Willebrand disease..
5:1165-1169.
2007
-
Evidence that pre-existent variability in platelet response to ADP accounts for 'clopidogrel resistance': a rebuttal..
5:1087-1088.
2007
-
Elevated prothrombin level and shortened clotting times in subjects with type 2 diabetes..
5:638-639.
2007
-
Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy..
5:632-634.
2007
-
Aprotinin is useful as a hemostatic agent in cardiopulmonary surgery: yes..
4:1875-1878.
2006
-
Circulating tissue factor accumulates in thrombi, but not in hemostatic plugs..
4:2092-2093.
2006
-
Phase 2, randomized, double-blind, placebo-controlled, multicenter clinical evaluation of recombinant human thrombin in multiple surgical indications..
4:2083-2085.
2006
-
Clinical outcomes with unfractionated heparin or low-molecular-weight heparin as bridging therapy in patients on long-term oral anticoagulants: the REGIMEN registry..
4:1246-1252.
2006
-
Platelet function analyzer (PFA)-100® closure time in the evaluation of platelet disorders and platelet function: Reply to a rebuttal [14].
4:1432.
2006
-
Platelet function analyzer (PFA)-100® closure time in the evaluation of platelet disorders and platelet function: Reply to a rebuttal [15].
4:1433-1434.
2006
-
The reactivity of paired plasma and serum samples are comparable in the anticardiolipin and anti-β2-glycoprotein-1 ELISAs. Reply to a rebuttal [17].
4:1435-1437.
2006
-
More on: are randomized clinical trials the only truth? Not always..
4:1167-1168.
2006
-
Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function..
4:312-319.
2006
-
The reactivity of paired plasma and serum samples are comparable in the anticardiolipin and anti-beta2-glycoprotein-1 ELISAs..
4:265-267.
2006
-
Characterization of a novel prothrombin variant, Prothrombin C20209T, as a modifier of thrombotic risk among African-Americans..
3:2357-2359.
2005
-
Viral respiratory tract infections increase platelet reactivity and activation: an explanation for the higher rates of myocardial infarction and stroke during viral illness..
3:2108-2109.
2005
-
Scanning electron microscopical observations of two novel hemostatic polymers..
3:1537-1539.
2005
-
Aspirin resistance: position paper of the Working Group on Aspirin Resistance..
3:1309-1311.
2005
-
Genetic factors contribute to bleeding after cardiac surgery..
3:1206-1212.
2005
-
First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: results of the XaNADU-ACS Trial..
3:439-447.
2005
-
One more way that mice and men are different..
3:448-449.
2005
-
Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia..
2:2133-2137.
2004
-
Potassium homeostasis in patients receiving prophylactic dose enoxaparin therapy..
2:1208-1209.
2004
-
Role of the gamma-carboxyglutamic acid domain of activated factor X in the presence of calcium during inhibition by antithrombin-heparin..
2:1127-1134.
2004
-
Impact of procoagulant concentration on rate, peak and total thrombin generation in a model system..
2:402-413.
2004
-
Initial experience with factor-Xa inhibition in percutaneous coronary intervention: the XaNADU-PCI Pilot..
2:234-241.
2004
-
Thrombus lysis by uPA, scuPA and tPA is regulated by plasma TAFI..
1:2000-2007.
2003
-
Interpretation of platelet inhibition by clopidogrel and the effect of non-responders..
1:1318-1319.
2003
-
The early antiplatelet effects of clopidogrel loading for coronary stenting and the long-term stability of inhibition..
1:1319-1321.
2003
-
Elevated plasma homocysteine leads to alterations in fibrin clot structure and stability: implications for the mechanism of thrombosis in hyperhomocysteinemia..
1:300-306.
2003
-
Aprotinin is useful as a hemostatic agent in cardiac surgery.
4:1875-1878.
2006
-
Bridging anticoagulation in patients who require temporary interruption of warfarin therapy for an elective invasive procedure or surgery (the bridge trial)
2015
-
Development and characterization of an RNA aptamer targeting FV/FVA
2015
-
Risk profiles and 1-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF
2015
-
Aptamer inhibition of an exosite of Factor (F)Xa or thrombin synergizes with non-aptamer inhibition of the catalytic site of FXa or thrombin, respectively
2013
-
Sonorheometry assessment of aspirin effects on platelet contributions to blood clot stiffness ex vivo in patients undergoing cardiopulmonary bypass procedures
2013
-
Individual anticoagulant aptamers uniquely impair thrombin generation and have a synergistic effect when used in combination
2011
-
Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia
2011